Detalhe da pesquisa
1.
Radioligand therapies in cancer: mapping the educational landscape in Europe.
Eur J Nucl Med Mol Imaging
; 50(9): 2692-2698, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37058168
2.
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients.
Int J Cancer
; 150(7): 1166-1173, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34605002
3.
On the Way for Patients with Prostate Cancer to the Best Use of PSMA.
Int J Mol Sci
; 23(5)2022 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35269620
4.
Production and Quality Control of [177Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials.
Molecules
; 27(13)2022 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35807385
5.
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial.
Br J Cancer
; 125(9): 1226-1232, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34333554
6.
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study.
Eur J Nucl Med Mol Imaging
; 48(1): 152-160, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32472437
7.
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Eur J Nucl Med Mol Imaging
; 48(10): 3260-3267, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33604690
8.
Theragnostic in neuroendocrine tumors.
Q J Nucl Med Mol Imaging
; 65(4): 342-352, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34881852
9.
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.
Br J Cancer
; 123(6): 982-987, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32669676
10.
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients.
Eur J Nucl Med Mol Imaging
; 47(13): 3008-3017, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32430583
11.
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Eur J Nucl Med Mol Imaging
; 47(4): 895-906, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838581
12.
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Eur J Nucl Med Mol Imaging
; 47(10): 2372-2382, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32123969
13.
Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis.
Int J Mol Sci
; 21(23)2020 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33260535
14.
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice.
Eur J Nucl Med Mol Imaging
; 46(5): 1102-1110, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30637501
15.
IntegoTM infusion system: cost effectiveness analysis focusing on dosimetry, sterility and management.
Q J Nucl Med Mol Imaging
; 63(2): 183-190, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27387379
16.
Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol.
Molecules
; 24(3)2019 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30754620
17.
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Eur J Nucl Med Mol Imaging
; 45(3): 348-354, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29110067
18.
68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients.
Eur J Nucl Med Mol Imaging
; 45(12): 2035-2044, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29922948
19.
Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index.
Eur J Nucl Med Mol Imaging
; 45(6): 923-930, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29387927
20.
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.
Eur J Nucl Med Mol Imaging
; 45(7): 1155-1169, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29484451